China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced positive topline results from the long-term safety Phase III study for its KX-826 (pyrilutamide) in alopecia. The trial met the primary endpoint with statistical significance and demonstrated the drug’s outstanding safety and efficacy.
Clinical Trial Results
At week 52, patients showed significant improvements in both target area non-vellus hair counts (TAHC) and target area non-vellus hair width (TAHW), with increases from baseline that were statistically significant (P<0.0001). Notably, 46% of subjects experienced a 10 hairs per cm² increase in TAHC, while 20% saw a 20 hairs per cm² increase.
Drug Profile
KX-826 is an androgen receptor (AR) antagonist developed for the treatment of androgenetic alopecia (AGA). Launched globally in July of last year, it is also the active ingredient in an exuberant-hair shampoo targeting AGA.-Fineline Info & Tech
Leave a Reply